In GTPI’s opinion, this concession is undeserved. The main argument is that the patent
lacks sufficiency disclosure, ie, it does not have the level of detail necessary for the
technology described therein to be reproduced by a person skilled in the art. This is
fundamental to justify the granting of the patent.
The antiretroviral drug dolutegravir, taken in conjunction with other drugs to suppress an HIV patient’s viral load and to stop them passing the virus to others, is considered one of the best HIV drugs available and has become the cornerstone of treatment in many richer countries since it was first introduced in the United States in 2013.
Thomas Folks spent years in his U.S. Centers for Disease Control and Prevention lab developing a treatment to block deadly HIV in monkeys. Then San Francisco AIDS researcher Robert Grant, using $50 million in federal grants, proved the treatment worked in people who engaged in risky sex.